Santa Monica, CA, April 09, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical
device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the
electrophysiology (EP) marketplace, today announced that Frank J. Quintero, a Los Angeles-based investor, joined the Advisory Board of the Company.
Mr. Quintero is a Principal at The Yucaipa Companies, a premier investment firm founded by Ron Burkle in 1986. His responsibilities as a Principal of the firm encompass deal origination,
negotiating transactions, investor relations and corporate communications. Working closely with The Yucaipa Companies' founder, Mr.
Quintero actively participated in multiple phases of the investment process since joining the firm. The Yucaipa Companies has
completed mergers and acquisitions valued at more than $35 billion.
Prior to joining The Yucaipa Companies, Mr. Quintero served as Special Assistant to California Governor Gray Davis. In this
position he served as a liaison to labor officials and business groups; as well as local, state, and national elected
officials. Mr. Quintero was also an advisor to Governor Davis on over 300 boards and commission appointments within the
California state government. Under Governor Davis' leadership the Appointments Unit placed more women and people of color in
appointed positions than any of California's previous governors.
Active in numerous statewide and local political campaigns, in 1998 Mr. Quintero worked as State Field Director for the
California Democratic Party Coordinated Campaign. As part of the three-person team managing a budget of several million
dollars, Mr. Quintero directed over thirty offices throughout the state and oversaw print, radio, and direct mail
advertising. His efforts on behalf of the Coordinated Campaign's “Get-Out-The-Vote” drive produced record voter registration
and turnout in low-income communities.
Based on his experience unifying divergent groups, Mr. Quintero was chosen as one of 60 Americans to receive a Marshall
Fellowship in 2001. He became part of a team of scholars and government officials brought together to advise European Union
member nations, NGOs, and the head of NATO on economic integration and immigration policy.
“Frank brings to us very impressive track record in investment, government and communications sectors. We are confident that
Frank’s many achievements and his strong relationships in the state of California will be a definite advantage to our growing
operations, ” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
The goal of the Advisory Board is to advise the leadership of BioSig on a range of subjects, including financing, strategy,
marketing, government affairs, partnerships and M&A. Current Members of the Board include Los Angeles-based political advisor
and business leader Mr. Sim Farar, San Francisco Bay area based Mr. Kent Bennett Williams, CEO and Principal at Vista Asset
Management, LLC, Texas-based Dr. Ramachandra Malya, Medical Director, and Los Angeles based investor, recording artist and a
songwriter D.A. Wallach.
“I have been impressed by BioSig’s innovative thinking and their dedication to advance medicine through novel technological
solutions. I look forward to working with the management and contribute my expertise to enhance the Company’s growth,” commented
Mr. Quintero.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to
improve the electrophysiology (EP) marketplace (www.biosig.com). Led by a proven management team and a veteran, independent Board of Directors,
Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to
address an unmet need in a large and growing market.
The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to
assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates
and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and
potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on
technology development and received FDA 510(k) clearance for the PURE EP™ System in August 2018.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or
more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product
candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking
statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual
Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free
of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Natasha Drapeau BioSig Technologies, Inc. Executive Vice President 12424 Wilshire Blvd, Ste 745 Los Angeles, CA 90025 ndrapeau@biosigtech.com 310-620-9320
